McGowan Institute for Regenerative Medicine
affiliated faculty member Douglas Kondziolka, MD (pictured), Peter J. Jannetta professor and vice chairman of neurological surgery at the University of Pittsburgh Medical Center (UPMC), is the principal investigator of the Phase 1/2a clinical trial testing a novel cell therapy product, SB623, in patients suffering from disability resulting from ischemic stroke. SB623 is a proprietary regenerative cell therapy from SanBio, Inc. consisting of cells derived from genetically engineered bone marrow stromal cells obtained from healthy adult donors. SB623 functions by producing proteins that aid the healing process.
SB623 has been shown to improve neurological behavior in preclinical models of stroke. In this study, safety and efficacy parameters will be evaluated, including improvements in motor function and cognitive status. The trial will evaluate 18 patients who have suffered an ischemic stroke within the past 6 to 24 months and have a motor neurological deficit.
"We are excited to be a part of this important new study offering a novel approach to therapy for patients suffering from ischemic stroke disability," said Dr. Kondziolka.
"Preclinical models have shown that SB623 restores function in animal models of stroke. With over 7 million stroke victims in the U.S. today, we are eager to explore the potential of SB623 in patients who may otherwise be permanently disabled," said Lawrence Wechsler, MD, chair, department of neurology at UPMC.
Illustration: McGowan Institute for Regenerative Medicine.
ClinicalTrials.gov: A Study of Modified Stem Cells in Stable Ischemic Stroke
Bio: Dr. Douglas Kondziolka